[Annual Report] Central and Eastern…
Fierce Biotech: Chinese Vaccine Developer…
OCT Clinical, a European CRO, is happy to announce that it has completed patient recruitment in an influenza vaccine study in record time.
This is a multicenter, double-blind, randomized phase III clinical trial that will run in two parallel groups. It aims to prove efficacy, safety and reactogenicity of the vaccine. The quadrivalent inactivated subunit adjuvanted influenza vaccine is developed by a full-cycle biopharmaceutical company with 20-years' successful experience in operating in the pharma market. The vaccine technology is unique and was developed twenty years ago.
Despite the tight schedule, the enrollment of 824 subjects was completed in record time. Participants include children aged from 6 to 35 months, who will be screened across 14 investigative centers. By now, vaccination of all volunteers has been completed, and the period of observation is underway.
'We are confident that our vast experience in influenza and vaccine studies will help us to provide our clients with qualified clinical services and reach all the milestones on time,' - Vitaly Gneyshev, Project Manager at OCT Clinical.
The OCT Clinical team is responsible for all aspects of conducting this study, including regulatory and logistics support, project management, site initiation and monitoring. This repeat business study is a result of previous successful collaboration between OCT Clinical and the Sponsor.